Related Experiment Videos
Inactivated poliovirus vaccine: current production methods and new developments.
Reviews of Infectious Diseases
|May 1, 1984
Summary
Advancements in biotechnology enable large-scale, cost-effective production of inactivated poliovirus vaccine (IPV). New methods promise safer, more potent vaccines and reduced vaccination costs, potentially using subunit approaches.
Area of Science:
- Biotechnology
- Vaccinology
- Virology
Background:
- Recent biotechnological progress has enabled industrial-scale production of inactivated poliovirus vaccine (IPV).
- Optimized cell culture techniques and large fermentors facilitate efficient virus cultivation.
- Improved purification and safety testing enhance vaccine quality.
Purpose of the Study:
- To detail advancements in inactivated poliovirus vaccine (IPV) production.
- To explore the potential for subunit poliovirus vaccines.
- To assess the economic and safety implications of new vaccine technologies.
Main Methods:
- Utilizing subcultured monkey kidney, Vero, or human diploid cells for virus multiplication.
- Implementing microcarrier culture techniques in large-scale fermentors (100-1,000 liters).
- Developing enhanced purification procedures and simplified safety/potency tests.
Main Results:
- Demonstrated production of potent IPV suitable for reduced vaccination schedules, alone or combined with DTP vaccine.
- Confirmed that viral proteins alone can induce neutralizing antibodies.
- Established feasibility of subunit vaccine production using recombinant DNA and synthetic antigens.
Conclusions:
- Biotechnological advancements have made IPV production more efficient and cost-effective.
- Potent IPV and potential subunit vaccines offer reduced vaccination schedules and costs.
- New production methods promise enhanced vaccine safety and affordability.